Drug Injury Claims Cause Actos Sales to Plunge
Reports surfaced early today that profits for Japan-based Takeda Pharmaceutical Co. have substantially declined.
Reports surfaced early today that profits for Japan-based Takeda Pharmaceutical Co. have substantially declined. One factor that several news sources, including Bloomberg Businessweek, have attributed to the company’s losses is the controversy surrounding its top-selling drug, Actos. Calls for the FDA to release cautionary warnings for the diabetes medication began to emerge after it was linked to an increased risk of bladder cancer. Takeda projects that its net income will plunge by over 30 percent over the course of the next four months.
Leading national plaintiffs’ firm Seeger Weiss LLP announced today that Jennifer Scullion, a 20-year litigation veteran and formerly a partner at Proskauer Rose, has joined the firm as partner in its New [...]December 8, 2016 By: Seeger Weiss read more